A look at promising new approaches in SCLC
First in a mini-series featuring some of the companies that presented CAR-NK cell data at AACR22
An emerging new and highly selective oncogenic target
Exploring future IO-IO combination strategies and life cycle management
The continuous evolution of BCMA CAR-T cell therapy products and how they are doing
When cell therapies and targeted therapies collide
Hot or not - 5 early stage trials with different agents and targets
A lion roar or whimper at the prospect of KRASi plus IO trials?
Can you have your immune cake and eat it?
Exploring new approaches to targeting cancer
It's time for an update on novel protein degraders
Can we improve the quality of T cells performance and boost outcomes?
The intriguing science behind a novel protein degrader platform
A look at a major phase 3 trial result and some of the nuances behind the data leading to a negative study
Part 2 of our mini-series on Next Generation CAR-T cells
What can we learn from various breast cancer trials?
Do we need to target the adenosine fog as well as TIGIT in NSCLC?
Can a genomic signature help select patients more accurately for DDR therapies?
It's time to tackle some intractable targets in oncology and elsewhere...
What are Novartis up to these days with their oncology pipeline and what are they excited about?
A look at why and how Relay's early oncology pipeline might be one to reckon with
What are Gritstone up to behind the scenes and where are they headed in the near-term?
What can deep learning techniques tell us about NASH, Parkinson's, Alzheimer's or even cancer?
Update on the T cell engager niche with an emerging agent of interest
Update on C4, Kymera, Novartis and Vividion
Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME
How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?
Update on the Novartis SHP2 inhibitor at ASCO21
A look at the first anti-cancer therapy with a radiopharmaceutical in advanced prostate cancer
Who's going to the masquerade ball and how might they fare in the future?
New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.
Bridging the DDR gap from AACR to ASCO
What can we learn from C4 Therapeutics monoDAC, CFT7455?
A look at Kymera's protein degrader pipeline
A look at the subtleties and nuances under the hood of the Arvinas PROTACs
What's hot on the DDR front and PARP inhibitor space at AACR21?
Capturing attention in the crowded protein degradation niche
Degrading oncogenic proteins with novel bacterial approaches
How prodrug technology can lead to improved delivery of potent chemotherapy in select tumour types
A novel approach to chemistry can potentially transform a therapeutic modality against cancer
How do we unleash more cytotoxic T cells against a cancer with a high unmet medical need?
Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore
A rock around the myeloma clock through the eyes of a KOL - what stood out and what did not?
Beyond CAR-T cell therapy there are novel bispecifics coming along so where and how will they fit in?
A look at what we can learn from the cilta-cel BCMA CAR-T cell therapy data and where things are likely headed
A critical look at the early stage BMS oncology pipeline
Commentary on engineered NK cells, including CAR-NK and memory-like NK cells
Expert commentary on new data relating to NK cell therapies - are they ready for prime time yet or not?
It's time to turn our attention to novel TKI approaches in hematologic malignancies
It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…
Rising stars become supernovas or disappear into a black hole of R&D - a look at what we can learn from one company's early stage compounds
A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape
Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies
How can we use metabolic reprogramming to enhance CAR T cell therapy?
Can we influence T cell fitness and performance by manipulating metabolic processes?
Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…
If we were to tackle CAR T cell therapy design differently, how would we go about doing it?
Can we make NK cells work harder with gene editing? It looks as though this will be a feasible strategy to pursue...
Will we have more success targeting IL-18 to boost anti-tumour immunoty than other cytokines?
An update on the CD20 x CD3 bispecific with expert commentary on data at ASCO EHA.
Highlights from various breast cancer trials and new pipeline developments
A look at Genentech's tiragolumab (anti-TIGIT) in advanced lung cancer
Dr Ross Camidge provides a critical review of ADAURA trial of osimertinib in adjuvant EGFR mutant lung cancer presented at the 2020 ASCO annual meeting.
From bench to bedside has many twists and turns along the way - an update on a longitudinal story we have been following for 5 years
Another fine example of how our understanding of the biology underpinning a certain type of cancer can lead to drugging the undruggable (no, it's not KRAS!)
What do we learn from the initial data with novel PROTAC technology?
Will CAR-NK cells follow CAR-T cell therapies and hit prime time?
A look at what a young up and coming biotech in the TIGIT space are doing and how they see their approach being differentiated from the competition.
A raft of updates on the R&D pipelines in the adenosine niche, plus a biotech company interview
New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.
One particular presentation stood out from the others at AACR20 this year
Some immune cells overlap in cancer and Covid-19 so what can we learn from them in order to make an impact?
When T cells stop working how can we get innate immune cells like NK cells to take up the slack and help track down tumours?
Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?
Can we learn from what a patient's tumour is telling us in terms of what the immune system is responding to in order to target it therapeutically?
An expert interview with a leading immunologist who discusses two translational opportunities with potential for cancer immunotherapy
An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche
Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
CAR T cell therapy for solid tumors is the cancer new product development equivalent of the quest for the "Holy Grail."
Interview with Dr Carl June on what the next decade holds for CAR T cells, cell therapy and genome engineering
Interview with Prof John Gribben at second European EHA EBMT CAR T cell therapy meeting in Sitges, Spain
Can innovative our ability to reinvigorate stalled CAR T cells affected by immune escape from CD19 loss or downregulation of BCMA?
Novel approaches in AML seek to overcome the challenges of the past and improve clinical outcomes.
Update on Kura Oncology's progress with tipifarnib and their emerging pipeline
Following the recent failure of Incyte's itacitinib in acute GVHD, we look at promising early developments following in their wake.
TIM-3 may have a role to play in myeloid hematologic malignancies such as AML and MDS. We explore the scientific rationale, competitive landscape, and initial clinical data.
A look at tucatinib, margetuximab and trastuzumab deruxtecan in HER2+ advanced MBC
A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.
Analysis and commentary of Nektar's IL-2 cytokine bempeg in combination with nivolumab in 1L advanced melanoma
What new things will we learn about the microbiome at SITC19?
KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib
Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?
What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?
On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...
How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...
There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.
As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.
Where are CDK4/6 inhibitors going and are there new opportunities for this class of agents outside of HR+/HER2- breast cancer?
What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...
Insights from a US KOL on the phase 3 PROfound trial exploring olaparib in mCRPC
A look at the FLAURA overall survival results and what we can learn from the phase 3 trial
Is Siglec-15 a key target in overcoming immunosuppression in some cancer patients?
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...
How do mission critical oncogenes cooperate and act in concert in cancer?
If we want to be able to drug oncogenes such as MYC then we need to figure out how they work and function to find the achilles heel
A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...
A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess
Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?
We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?
Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?
Is T cell therapy like Game of Thrones?
What can we learn from biomarkers and immune profiling in patients receiving bempeg, a CD122-directed pegylated IL-2 therapy
How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?
Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?
New data suggests there may be value in targeting CD73 as well as the A2A receptor in certain tumour types...
How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents
Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche
A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche
Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.
A look at inducing apoptosis of cancer cells via CDK7 inhibition and the future for rational combo approaches.
Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.
Can gamma delta T cells be effective as a therapeutic in GBM?
Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.
As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative
Neutrophils may be responsible for inducing immunosuppression and resistance to checkpoint therapies so how do we target them in the clinic?
With the help of a leading pathologist, we examine the challenges associated with PD-L1 and TMB as biomarkers for patient selection
Having a companion diagnostic is important for precision medicine, but can they accurately predict who is most likely to respond to cancer immunotherapy?
Do we need to target Tregs in order to get more anti-cancer efficacy with immunotherapy? We take a look at what we've learnt about this niche.
Can γδ T cells be employed as a therapeutic against cancer?
TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
Can we make novel allogeneic cell therapies with γδ T cells? We find out!
Targeting STING in cancer with a systemic small molecule approach? What's the story?
What does a next generation STING agonist look like and what issues is it attempting to address?
An upcoming small biotech focused on IO targets with their novel platform approach
Drugging the undruggable with creative approaches to molecule development
How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.
A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18
Can we improve on the tolerability of the nivolumab-ipilimumab regimen by designing better a checkpoint inhibitor?
Achilles Therapeutics is an emerging biotech in the cell therapy space that is based on truncal neoantigens
Initial results from the neon NEO-PV-01 phase 1B trial presented by Dr Patrick Ott
With new data on the blood-based TMB test at ESMO, what can we learn about this approach?
A discussion about the impact of the olaparib on the PARPi niche based on the findings of the SOLO1 trial
Can we use technology to squeeze more out of B cells to generate an army of killer T cells?
The changing face of renal cell cancer from several perspectives
Beyond PD-1 and CTLA4 there are other checkpoint and IO targets being investigated. We take a look at one of the promising ones...
An in-depth look at Adaptimmune's TCR T cell therapy program
One of the ongoing challenges with cancer immunotherapy is monitoring response to treatment. Even if you…
Bringing together disparate notes on cytokines and how they can be useful as an immunotherapy partner.
The latest part in our cytokine mini-series explores the potential for incorporating them in CARs or combining with checkpoint blockade through the lens of an expert in the field...
What can we learn from the updated Nektar NKTR-214 data presented at #ASCO18?
Update on TLR9 as a target and what we learn from the latest clinical data
Thoughts, reflections and learnings from the recent phase 3 lung cancer readouts from a lung cancer specialist...
Dr Gilberto Lopes discusses the KEYNOTE 042 and 189 trials in first-line non-small cell lung cancer (NSCLC).
A look at the history of CAR T cell therapy design and where things are headed in the future with one of the original cell therapy pioneers
A look at path to market strategies open to a small biotech in the CAR-T cell space
How do we drive more T cells into the tumour? Here's one company who are looking to do just that.
Going beyond PD-1, PD-L1 and CTLA-4 to explore other inhibitory checkpoint targets that may be useful in the clinic
A look at various lessons from recent IO trials and how they can applied to new readouts expected at ASCO18
A look at how basic and translational evidence points towards TGFβ as a possible new target for IO combos in some tumour types
A look at one way with which we can target the tumour microenviroment to improve response of cancer immunotherapy
What can we learn from the TRACERx studies in lung and renal cancers? Quite a lot, it seems...
4 KOLs tell us what they really thought about the 3 studies in 1L NSCLC presented at AACR18
A look at TMB as an emerging biomarker for cancer immunotherapy - is it ready for prime time?
An in-depth look at the French biotech company Innate Pharma and where they are now two years on from our last look at their IO pipeline.
A look at what Gamida Cell, an up and coming cellular and innate immunotherapy company are up to...
A look at targeting NK cells with immune agonists, cytokines and adoptive cell therapies
A look at the history of NK cell development and where we're going in future with this IO approach
A look at an emerging area for biomarkers and stealth cancer therapeutics
A look at innate approaches to stimulating the immune system including IL-15 agonists
Insights from researchers in the CD47 niche - what do they really think?
Will apalutamide and enzalutamide make headway in the M0 prostate cancer setting?
Interview with Dr Daniel George on Phase 3 PROSPER trial results
Expert interview with Dr Glen Barber reignites the controversy over whether STING agonists could cause metastasis in cancer patients.
Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.
A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences
A look at how new approaches in synthetic biology could revolutionise cell therapy in solid tumours
Interview with Syros Pharma CEO Dr Nancy Simonian
New approaches that enter a market unexpectedly can disrupt the status quo and push out more severe therapies to later lines of treatment
A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field
Where is the venetoclax BCL-2 program going in hematologic malignancies?
An interview with Dr John Leonard exploring his thoughts on some of the key lymphoma data at #ASH17
As we see new readouts emerge with different doublets and triplets in CLL, how will they impact the treatment landscape?
The first phase 3 trial in 1L NSCLC to hit the PFS endpoint is Genentech's IMpower150. What can we learn from this study?
A look at loss of heterozygosity and what it means for new lung cancer therapies
A look at the cabiralizumab plus nivolumab combination in PDAC at SITC over the weekend
A look st Syndax's entinostat and what happens when given in combination with pembrolizumab in melanoma and lung cancer
A look at Nektar's promising IO portfolio and what's next for the up and coming biotech
A CAR T cell therapist's perspective on the Juno JCAR015 ROCKET dataset
A look at some of the main events from the first day at SITC 2017 - including Juno's ROCKET data.
Can we address inhibitory factors that dampen NK cells to enhance the anti-cancer effect on tumours?
A look at what's different about exceptional responders in PDAC and what can we learn about neoantigen approaches here?
A look at the latest developments in cancer immunotherapy in ovarian cancer, with a particular focus on neoepitopes and cancer vaccines.
Interview with Prof Kees Melief, CSO ISA Immune System Activation Pharmaceuticals
A look at Ugur Sahin's BioNTech and personalized mRNA vaccines
Genentech have several cancer vaccine collaborations in place, where do they see the future going in this niche?
Part 1 of a new mini-series on cancer vaccines. This one covers an update on Neon's neoantigen approach...
A look at the last day of ESMO17 with key data on cancer vaccines, checkpoint and targeted therapies to explore
A look at what's happening with Cellectis and their clinical trial program with CD19 and CD123 CARs.
What does the future hold for Cellectis and allogeneic "off the shelf" CAR T cell therapy?
Gene editing looks set to become entrenched in allogeneic CAR T cell development, so what's new?
Does timing and sequencing of immune agonists impact their effect when given with checkpoint blockade?
A look at various factors that can influence cancer immunotherapy trials through the lens of an immunologist
A look at the role of pre-existing immunity in cancer immunotherapy trial readouts at ASCO17
Jumpstarting the immune system with a synthetic immunity approach - how can we do this?
In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.
Update on Nektar Therapeutics IO portfolio and a look at their burgeoning autoimmune disorder pipeline
How we could use our immune system against Alzheimer's?
A look at the intersection of epigenetics and cancer immunotherapy - what can we learn and where are we going in this niche?
A look at an up and coming small cap biotech developing targeted and immunotherapy agents for the treatment of cancer.
Why did the IMvigor211 phase 3 trial with atezolizumab in UBC fail? BSB spoke to Prof Tom Powles.
A look at how liver mets can negatively impact cancer immunotherapies
What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?
What's new in the sarcoma space? Which novel approaches are worth watching out for?
Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...
A look at checkpoint blockade in early stage breast cancer - encouraging or not?
A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO
Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?
A look a one company's approach to DDR and potential combination opportunities in this niche
A look at another approach for turning cold into hot (or warmer) tumours with cancer vaccines.
A fireside chat with a leading KOL involved in cancer research on resistance.
A look at a promising biotech in the neoantigen space - what's their approach and how might it fare?
With 'liquid biopsies' on the rise, we take a look at another potential candidate that could be useful - exploring exosomes.
A candid look at new approaches being explored in cold tumours using prostate cancer as an example
An interview with Dr Jonathan Lim, Ignyta on TRK/ROS/ALK inhibition
Through the keyhole with a look at AZN and MedImmune's IO portfolio
Expert interview at AACR17 with Dr Julie Brahmer on lung cancer immunotherapy resistance and preview of ASCO17 abstracts
Encouraging new developments in GBM with a novel CAR T cell therapy
How do we overcome resistance to cancer immunotherapies? Here, we have an in-depth interview with a thought leader in this space.
Dr Daniel Chen from Roche/Genentech shares his vision for the future of cancer immunotherapy at AACR17.
Interview with Professor Peter Schmid, Barts Cancer Institute.
A look at cancer immunity and the new framework for exploring the cancer-immune setpoint.
Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...
A look at the deeper side of research - how the spliceosome and RNA splicing may be useful in cancer research.
Going beyond proteasome inhibitors and IMiDs in multiple myeloma - what novel targets are attractive?
What we learnt at ASH16 on how to better target the tumour microenvironment in lymphoid malignancies.
Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches
A draft manifesto for IO in cancer research and what we need to learn
2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...
How crowdsourcing data from breast cancer patients may help future clinical R&D
Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?
SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.
SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.
Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens
First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.
Interview with Dr Stephan Grupp on the data he presented at ASH16 and what the future may hold for CAR T cell therapy in pediatric ALL
A look at some promising agents in new product development emerging in early CLL trials
How are recently approved novel therapies impacting the CLL landscape and where are we going next?
A look at the latest data for a CD79b targeted ADC in lymphomas
Tackling heterogeneity in older people with AML using novel targeted therapies.
#LeonardList showcases 10 Lymphoma Abstracts at ASH16
Without effector T cells in the tumour, checkpoints won't work. So how do we attract more in? Here's one way to do it...
How will glycomics impact cancer research? Some interesting new developments are emerging in this field
Can biomarkers help us improve clinical trial outcomes?
How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?
Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented
Yesterday saw the FDA approval of atezolizumab (Tecentriq) for the second-line treatment of metastatic…
What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.
Audio Slideshow tour of HalioDx lab that shows how digital pathology is used to calculate Immunoscore an immune based colon cancer assay
Interview with Dr Eric Pamer on impact of the microbiota on the innate and adaptive immune systems and future directions.
New research shows potential of cell therapy with allogeneic memory-like natural killer NK cells in AML.
Corvus Pharmaceuticals accelerates development of A2A receptor antagonist CPI-444 that could improve checkpoint responses.
Interview with Prof Ton Schumacher at scientific meeting to celebrate 40 years of Centre d’Immunologie de Marseille-Luminy (CIML).
Interview with Professor François Romagné, Scientific Director of MI-mAbs, an immuno-oncology drug discovery venture in the Marseille Immunopôle cluster.
Interview with Innate Pharma CEO Dr Hervé Brailly on clinical trial readouts expected and his vision for company
Professor Eric Vivier is Director of the Centre d’Immunologie de Marseille-Luminy and a co-founder of Innate Pharma and the Marseille Immunopôle. He is a leading researcher in the field of innate immunity.
Interview with HalioDx CEO Vincent Fert on commercial strategy for Immunoscore diagnostic test.
Interview with Prof Fran Balkwill from Barts Cancer Institute on 3D modelling of the tumor microenvironment in ovarian cancer
Part 2 of interview with PsiOxus Therapeutics CEO Dr John Beadle discusses corporate strategy and challenges faced by an emerging biotech company.
An innovative and promising approach to cancer immunotherapy using adenoviruses to deliver multiple warheads to tumours
Cary Pfeffer of Third Rock Ventures describes how a novel neoantigen vaccine in academia transitioned into a commercial company with exciting prospects...
This is the second in our mini-series on neoantigens and looks at whether neoantigen based cancer vaccines can make a difference in the treatment of solid tumors.
Can we turn a cold tumour into a hot one where some patients can respond to therapy?
An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.
What to make of the various combination trials presented at ASCO 2016?
Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas?
We asked experts at AACR what they really thought...
How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!
A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target
Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.
A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!
At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.
Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...
Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy
Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”
Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy
Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL
How do we decide how to incorporate the newly approved drugs in Multiple Myeloma and what's the next wave of therapies we can expect to see evolve?
Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?
A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.
An interview with Seattle Genetics CEO, Dr Clay Siegall on CD19A ocular toxicity and the competition from checkpoint inhibitors in Hodgkin's lymphoma.
An in-depth look at the FLT3 inhibitor midostaurin and its potential impact on the treatment for AML.
ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.
A look at the new CLL 17p deletion data at ASH in the late breaker session
Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.
Part 1 of an interview with Prof Waseem Qasim.
At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.
Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations
Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.
Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance
At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...
Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL
Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.
Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.
At the 2015 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting Barcelona on Friday, Dr Stephen Hauser (UCSF) presented the data for octrelizumab, an anti-CD20 monoclonal antibody, on behalf of the investigators in the OPERA trial.
Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma
Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types
Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).
Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.
Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer
Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours
We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...
Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.
ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.
Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.
The results of the TERRAIN prostate cancer clinical trial data were presented at the 2015 European Association of Urology (EAU) Congress in Madrid today.
What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?
Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.
Yumanity seeks to transform drug discovery for neurodegenerative diseases caused by protein misfolding.
Transcription factors are becoming a new buzzword in cancer research - why are they important for drug development?
Bluebird bio is an emerging biotech company with a novel lentiglobin gene therapy in development that could revolutionize the treatment of beta-thalassemia and sickle cell disease.
What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.
Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer
What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?
At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.
Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.
Several new agents in development emerged for the treatment of aggressive NHL (DLBCL and FL), including SGN-CD19A, polatuzumab vedotin and pinatuzumab vedotin.
There have been no new therapies in urothelial bladder cancer for 30 years - until now...
Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.
The new race to market in advanced prostate cancer is in the M0 asymptomatic space. Several AR antagonists are competing to run trials here but will they lead to men living longer or not?
Enzalutamide significantly decreases the risk of death and delays progression in the PREVAIL trial
Agios Pharmaceuticals is focused on developing new therapies that target mutations in cancer metabolism, including IDH 1 and 2 for AML and Glioblastoma.
Will they be successful despite the huge complexity involved in the underlying processes?
UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies.
At ASH, the impressive data from adult and pediatric ALL was presented.
This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.
Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.
FDA Office of New Drugs Director John Jenkins discusses the benefits of the Breakthrough Therapy designation and some of the challenges the agency faces in administering it.
John K. Jenkins, MD, Director of the Office of New Drugs, Center for Drug Evaluation and Research at the FDA offers a senior management perspective on what is a breakthrough?
Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.
An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).
It's exciting times in Chronic Lymphocytic Leukemia (CLL) with a lot of new data expected at the forthcoming 2013 annual meeting of the American Society of Hematology (#ASH13) in New Orleans. At ASCO 2013, Dr Susan O'Brien shared her thoughts on several new CLL drugs in development including ABT-199, ibrutinib, idelalisib, AV-292, obinutuzumab and IP-145.